Alba OEM Solutions
Your Vision, Our Expertise:
Tailored OEM solutions for success
Partnering with Alba means leveraging a long, successful history as a OEM supplier.
For over 30 years, Alba has developed, manufactured and marketed high-wuality products for use in transfusion diagnostics.
In addition to directly supplying an expansive network of labs around the world, Alba also prpovides a range of intermediate products for blood typing or related applications on an Original Equipment Manufacturer (OEM) basis.
Alba draws upon the depth of talent across business functions to drive effectiveness and efficiency. This level of expertise across functional areas ensures success throughout the development process.
Considering Alba as an OEM partner? Choose from an extensive list of partnering capabilities.
Partner with Alba
Would you like to learn more about the possibility of partnering with us on your projects? Use the button below to reach out to our team of experts to leverage our expertise to bring your vision to life.
Trending Topics
Recent press, briefings and insights helping you stay informed on AliveDx news.
-
AliveDx announces U.S. Food and Drug Administration (FDA) 510(k) submission for its MosaiQ AiPlex® Vasculitis (VAS) assay.
Eysins, Switzerland, September 2nd, 2025 AliveDx, the global in-vitro diagnostics company that aims to transform patient care, today announces that it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex® Vasculitis (VAS)
-
AliveDx registers MosaiQ®, its Instrument for Multiplex Testing of Autoimmune Diseases, Allergies and Beyond, as a Class II Exempt Device with the U.S. Food and Drug Administration (FDA)
The MosaiQ instrument is a next-generation, continuous random-access immunoassay platform offering labs automation, simple workflows, fast, multiplexed results and actionable insights for complex-to-diagnose conditions. Eysins, Switzerland – August 25, 2025 – AliveDx, the global in-vitro diagnostics company dedicated to advancing
-
AliveDx Suisse S.A. and Transmedic sign second distribution agreement for Indonesia, Thailand, and Singapore
AliveDx Suisse S.A. (AliveDx) and Transmedic Indonesia, Thailand and Singapore have signed a second distribution agreement, enabling Transmedic to distribute the LumiQ® solution across these markets. The distribution agreement takes effect immediately. This partnership underscores AliveDx’s dedication to expanding its
-
AliveDx Suisse S.A. and Vital Care Production Distribution et Logistique SPA, sign a second distribution agreement for Algeria
AliveDx Suisse S.A. (AliveDx) and Vital Care Production Distribution et Logistique SPA (Vital Care), have signed a second distribution agreement, which will enable Vital Care to distribute the LumiQ® solution in Algeria. The distribution agreement takes effect immediately. This partnership
-
AliveDx Suisse S.A. and Medical Supplies and Services Co. Ltd. sign a Strategic Distribution Agreement in Saudi Arabia
AliveDx Suisse S.A. (AliveDx) is pleased to announce the signing of a strategic distribution agreement with Medical Supplies and Services Co. Ltd. (MediServ). This agreement enables MediServ to distribute the MosaiQ® and LumiQ® solutions across Saudi Arabia, with immediate effect.
-
MosaiQ AiPlex® Vasculitis assay, now available for clinical use in the European Union and other CE mark accepting countries.
AliveDx achieves IVDR-CE Mark for a multiplexed MosaiQ AiPlex® Vasculitis (VAS) assay, designed to advance the testing of Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides and Anti-GBM (Goodpasture’s) disease and improve time to results to support diagnosis of autoimmune vasculitis. Eysins, Switzerland,
